Triple-dose regimen may permanently clear HIV in infected newborns
Researchers at Oregon Health & Science University have identified a potential one-time treatment regimen that could permanently clear HIV in newborns. The study, published in Nature Microbiology, suggests that combining neutralizing antibodies with antiretroviral therapy and leronlimab may be effective.
Why it matters
This breakthrough could lead to immediate clinical trials, offering a path to eliminate HIV infection in newborns globally.
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Catalina Herrera from Pexels Every year, more than 120,000 newborns worldwide contract HIV, creating a global health burden that requires lifelong treatment for millions of people—assuming they have access and can afford it. New research led by Oregon Health & Science University suggests another possibility: a one-time regimen of therapies given to newborns within three days of birth to permanently clear the virus. The research is published today in the journal Nature Microbiology .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in